Last updated on July 2018

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy


Brief description of study

In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled. HBsAg/anti-HBs level, HBeAg/anti-HBe level, Serum HBV DNA load and alanine transaminase level will be test every year from the second year to the fifth year after the ending of peginterferon alfa treatment, and long-term benefit of interferon treatment will be evaluated.

Clinical Study Identifier: NCT03181113

Find a site near you

Start Over